Dianthus Therapeutics (DNTH) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company strategy and therapeutic focus

• Developing next-generation complement therapeutics for severe autoimmune disorders, focusing on the classical pathway while leaving lectin and alternative pathways intact.

• Lead program DNTH103 is a potent monoclonal antibody targeting only the activated form of C1s, designed for infrequent, self-administered dosing.

• Phase I data showed a long half-life (60 days) and potential for a differentiated safety profile.

• Currently running two phase II programs (myasthenia gravis, MMN) and preparing a third in CIDP.

• Strategy aims to maximize efficacy while minimizing infection risk and avoiding boxed warnings.

Key drivers of investor interest and funding

• Strong execution: rapid transition from stealth mode to public company, completion of phase I, and initiation of multiple phase II programs.

• External validation: competitor data (argenx, Sanofi) de-risked programs and confirmed efficacy of classical pathway inhibition.

• Secured $230 million PIPE, extending financial runway into the second half of 2027, beyond the first major data catalyst.

• Confidence built through execution, external catalysts, and removal of financing overhang.

Scientific rationale and clinical development

• DNTH103 designed to target activated C1s, reducing unnecessary drug use and enabling subcutaneous delivery.

• MG chosen as first indication due to large market, clear regulatory path, and potential for best-in-class differentiation.

• All three lead indications (MG, CIDP, MMN) are neuromuscular, allowing clinical and commercial synergies.

• Biological rationale for classical pathway inhibition in MG is strong, supported by in vitro data and KOL feedback.

• Phase II MaGic trial in MG is underway, testing two doses, with data expected in the second half of next year.